שולי רווח תפעולי ממכירות: Liminatus Pharma Inc. (LIMN)

The operating profit margin history of Liminatus Pharma (LIMN) demonstrates the potential of CAR-T therapy against complex solid tumors. However, total outsourcing of research to external vendors and the anticipation of the start of gastric cancer trials are creating pressure. The 0.00 level reflects the current profitability magnitude, where pre-commercialization operating expenses have already been priced in by the market.
Liminatus Pharma - פילוחים אנליטיים ומדדי מפתח (LIMN)

Investors are assessing the resilience of Liminatus Pharma (LIMN) through its operating margin, calculated as the ratio of operating income before interest and taxes to total revenue. By analyzing the company's operating margins, one can identify the impact of geopolitical risks and supply chain disruptions of Asian raw materials on the actual production efficiency of immuno-oncology drugs.